One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA
Authors' conclusion
The cardiorenal benefits might be magnified with the combination therapy of SGLT2i and GLP-1RA when compared with monotherapy of either agent. Further investigations are needed to validate the findings.
Study context
- Population
- Patients with T2D5 RCTs, 10 post hoc analyses, 1 observational study
- Comparison
- SGLT2i + GLP-1 RA combination therapy vs SGLT2i or GLP-1 RA monotherapy
- Outcome
- Cardiorenal outcomes:
- Cardiovascular outcome
- Composite renal adverse events
Methodological detailsrandom-effects model, PubMed, Web of Science, Embase, Cochrane CENTRAL and Clinicaltrial.gov searched from inception to June 2024
- Random-effects model
- PubMed, Web of Science, Embase, Cochrane CENTRAL and Clinicaltrial.gov searched from inception to June 2024
Pooled result
As reported in the abstract
Composite cardiovascular outcome
Relative risk (95% CI)P value
Combination therapyvs SGLT2i monotherapy
0.57(0.38–0.86)
P = 0.008Combination therapyvs GLP-1RA monotherapy
0.77(0.65–0.91)
P = 0.002Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Composite renal adverse eventsCombination therapyvs SGLT2i monotherapy | 0.69 (0.59–0.82) | P < 0.001 | |
| Composite renal adverse eventsCombination therapyvs GLP-1RA monotherapy | 0.66 (0.53–0.83) | P < 0.001 | |
| HF-related outcomesCombination therapyvs GLP-1RA monotherapy | 0.63 (0.51–0.77) | P < 0.001 | |
| All-cause mortalityCombination therapyvs GLP-1RA monotherapy | 0.66 (0.50–0.88) | P = 0.004 | |
| 0.512Relative risk (log scale) |
Original publication
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA. Diabetes Obes Metab. Published 21 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →